Your browser doesn't support javascript.
loading
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
Starr, Tyler N; Czudnochowski, Nadine; Liu, Zhuoming; Zatta, Fabrizia; Park, Young-Jun; Addetia, Amin; Pinto, Dora; Beltramello, Martina; Hernandez, Patrick; Greaney, Allison J; Marzi, Roberta; Glass, William G; Zhang, Ivy; Dingens, Adam S; Bowen, John E; Tortorici, M Alejandra; Walls, Alexandra C; Wojcechowskyj, Jason A; De Marco, Anna; Rosen, Laura E; Zhou, Jiayi; Montiel-Ruiz, Martin; Kaiser, Hannah; Dillen, Josh R; Tucker, Heather; Bassi, Jessica; Silacci-Fregni, Chiara; Housley, Michael P; di Iulio, Julia; Lombardo, Gloria; Agostini, Maria; Sprugasci, Nicole; Culap, Katja; Jaconi, Stefano; Meury, Marcel; Dellota, Exequiel; Abdelnabi, Rana; Foo, Shi-Yan Caroline; Cameroni, Elisabetta; Stumpf, Spencer; Croll, Tristan I; Nix, Jay C; Havenar-Daughton, Colin; Piccoli, Luca; Benigni, Fabio; Neyts, Johan; Telenti, Amalio; Lempp, Florian A; Pizzuto, Matteo S; Chodera, John D.
Affiliation
  • Starr TN; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Czudnochowski N; Vir Biotechnology, San Francisco, CA, USA.
  • Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
  • Zatta F; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Park YJ; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Addetia A; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Pinto D; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Beltramello M; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Hernandez P; Vir Biotechnology, San Francisco, CA, USA.
  • Greaney AJ; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Marzi R; Department of Genome Sciences, University of Washington, Seattle, WA, USA.
  • Glass WG; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Zhang I; Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Dingens AS; Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bowen JE; Tri-Institutional PhD Program in Computational Biology and Medicine, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.
  • Tortorici MA; Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Wojcechowskyj JA; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • De Marco A; Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Rosen LE; Vir Biotechnology, San Francisco, CA, USA.
  • Zhou J; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA.
  • Kaiser H; Vir Biotechnology, San Francisco, CA, USA.
  • Dillen JR; Vir Biotechnology, San Francisco, CA, USA.
  • Tucker H; Vir Biotechnology, San Francisco, CA, USA.
  • Bassi J; Vir Biotechnology, San Francisco, CA, USA.
  • Silacci-Fregni C; Vir Biotechnology, San Francisco, CA, USA.
  • Housley MP; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • di Iulio J; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Lombardo G; Vir Biotechnology, San Francisco, CA, USA.
  • Agostini M; Vir Biotechnology, San Francisco, CA, USA.
  • Sprugasci N; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Culap K; Vir Biotechnology, San Francisco, CA, USA.
  • Jaconi S; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Meury M; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Dellota E; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Abdelnabi R; Vir Biotechnology, San Francisco, CA, USA.
  • Foo SC; Vir Biotechnology, San Francisco, CA, USA.
  • Cameroni E; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.
  • Stumpf S; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.
  • Croll TI; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Nix JC; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
  • Havenar-Daughton C; Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK.
  • Piccoli L; Molecular Biology Consortium, Advanced Light Source, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
  • Benigni F; Vir Biotechnology, San Francisco, CA, USA.
  • Neyts J; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Telenti A; Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Lempp FA; Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium.
  • Pizzuto MS; Vir Biotechnology, San Francisco, CA, USA.
  • Chodera JD; Vir Biotechnology, San Francisco, CA, USA.
Nature ; 597(7874): 97-102, 2021 09.
Article in En | MEDLINE | ID: mdl-34261126
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cross Reactions / Immune Evasion / Spike Glycoprotein, Coronavirus / Broadly Neutralizing Antibodies / SARS-CoV-2 / COVID-19 Limits: Adult / Aged / Animals / Female / Humans / Male / Middle aged Language: En Journal: Nature Year: 2021 Document type: Article Affiliation country: United States Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cross Reactions / Immune Evasion / Spike Glycoprotein, Coronavirus / Broadly Neutralizing Antibodies / SARS-CoV-2 / COVID-19 Limits: Adult / Aged / Animals / Female / Humans / Male / Middle aged Language: En Journal: Nature Year: 2021 Document type: Article Affiliation country: United States Country of publication: United kingdom